Moreover, some studies have revealed through clinical trials the great potential of Wee1 inhibitors in combination with poly ADP‐ribose polymerase inhibitors as resistance to first‐line therapy in clinical SCLC.21 The gene discussed is WEE1; the disease is small cell lung carcinoma.